Oppenheimer & Co. Inc. boosted its stake in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 72.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,706 shares of the company’s stock after buying an additional 30,240 shares during the period. Oppenheimer & Co. Inc.’s holdings in TherapeuticsMD were worth $378,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of TXMD. Bank of New York Mellon Corp increased its position in TherapeuticsMD by 12.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 22,892,018 shares of the company’s stock valued at $120,642,000 after buying an additional 2,574,120 shares in the last quarter. Sphera Funds Management LTD. bought a new position in TherapeuticsMD during the 1st quarter valued at approximately $4,176,000. Vanguard Group Inc. increased its position in TherapeuticsMD by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock valued at $70,574,000 after buying an additional 515,992 shares in the last quarter. JPMorgan Chase & Co. increased its position in TherapeuticsMD by 2.5% during the 1st quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock valued at $98,827,000 after buying an additional 329,245 shares in the last quarter. Finally, State Street Corp increased its position in TherapeuticsMD by 6.9% during the 1st quarter. State Street Corp now owns 3,903,491 shares of the company’s stock valued at $28,105,000 after buying an additional 253,237 shares in the last quarter.

Shares of TherapeuticsMD Inc (NASDAQ TXMD) opened at 6.60 on Friday. The company’s market cap is $1.35 billion. The firm has a 50 day moving average price of $5.97 and a 200-day moving average price of $5.59. TherapeuticsMD Inc has a 12-month low of $3.50 and a 12-month high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.91 million. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The business’s quarterly revenue was down 3.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.11) earnings per share. On average, equities analysts expect that TherapeuticsMD Inc will post ($0.43) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/17/oppenheimer-co-inc-has-378000-position-in-therapeuticsmd-inc-txmd.html.

In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of TherapeuticsMD stock in a transaction dated Wednesday, August 30th. The shares were acquired at an average cost of $5.99 per share, with a total value of $29,950.00. Following the completion of the transaction, the director now owns 3,555 shares in the company, valued at approximately $21,294.45. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of analysts have commented on TXMD shares. Deutsche Bank AG reissued a “buy” rating and issued a $10.00 target price on shares of TherapeuticsMD in a report on Wednesday. Jefferies Group LLC reissued a “buy” rating and issued a $15.00 target price on shares of TherapeuticsMD in a report on Friday, September 8th. Morgan Stanley started coverage on TherapeuticsMD in a report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 target price for the company. Cantor Fitzgerald reissued a “buy” rating and issued a $33.00 target price on shares of TherapeuticsMD in a report on Monday, September 4th. Finally, Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $10.00 target price on shares of TherapeuticsMD in a report on Thursday, August 31st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. TherapeuticsMD currently has an average rating of “Buy” and an average price target of $14.88.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.